Waters Parkerson & CO. LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 1.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 404,812 shares of the biopharmaceutical company’s stock after buying an additional 4,327 shares during the period. Waters Parkerson & CO. LLC’s holdings in Pfizer were worth $14,687,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Private Capital Group LLC boosted its position in Pfizer by 4.8% during the second quarter. Private Capital Group LLC now owns 26,685 shares of the biopharmaceutical company’s stock worth $968,000 after acquiring an additional 1,215 shares during the last quarter. Texas Yale Capital Corp. boosted its position in Pfizer by 1.5% during the second quarter. Texas Yale Capital Corp. now owns 83,436 shares of the biopharmaceutical company’s stock worth $3,027,000 after acquiring an additional 1,255 shares during the last quarter. Ken Stern & Associates Inc. boosted its holdings in shares of Pfizer by 7.2% in the 2nd quarter. Ken Stern & Associates Inc. now owns 18,906 shares of the biopharmaceutical company’s stock valued at $686,000 after purchasing an additional 1,266 shares during the last quarter. Abbrea Capital LLC boosted its holdings in shares of Pfizer by 2.0% in the 2nd quarter. Abbrea Capital LLC now owns 64,420 shares of the biopharmaceutical company’s stock valued at $2,337,000 after purchasing an additional 1,274 shares during the last quarter. Finally, Modera Wealth Management LLC boosted its holdings in shares of Pfizer by 4.8% in the 2nd quarter. Modera Wealth Management LLC now owns 27,723 shares of the biopharmaceutical company’s stock valued at $1,006,000 after purchasing an additional 1,276 shares during the last quarter. 68.64% of the stock is owned by institutional investors.
Shares of PFE stock opened at $43.14 on Monday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.15 and a current ratio of 1.43. The company has a market cap of $256.81 billion, a price-to-earnings ratio of 16.28, a P/E/G ratio of 2.15 and a beta of 0.88. Pfizer Inc. has a 52 week low of $33.20 and a 52 week high of $45.81.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be issued a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, November 8th. This represents a $1.36 annualized dividend and a yield of 3.15%. Pfizer’s dividend payout ratio (DPR) is currently 51.32%.
In related news, major shareholder Pfizer Inc bought 55,556 shares of the company’s stock in a transaction on Monday, October 15th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the acquisition, the insider now owns 21,976,484 shares of the company’s stock, valued at approximately $395,576,712. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.06% of the company’s stock.
Several equities analysts recently weighed in on the stock. Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 27th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, July 31st. Goldman Sachs Group reaffirmed a “neutral” rating and set a $42.00 price objective on shares of Pfizer in a research report on Wednesday, August 1st. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Monday, August 6th. Finally, Deutsche Bank set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, August 21st. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have assigned a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and an average target price of $42.67.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
See Also: What is the Book Value of a Share?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.